By Fineline Cube 
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 chemical drug KH607, aimed at treating postpartum depression.
KH607: A Promising Treatment for Postpartum Depression
KH607 is an in-house developed oral small molecule γ-aminobutyric acid A (GABA A) receptor positive allosteric modulator. It was approved for clinical study in depression in the US in 2023. This approval signifies a significant step forward in the development of new treatment options for postpartum depression.-Fineline Info & Tech